Labcorp to acquire OPKO’s BioReference assets for up to $872 million
Labcorp agreed to buy the laboratory testing businesses of OPKO Health’s BioReference unit for $722 million in cash, with an additional earn‑out of up to $150 million tied to the 4Kscore prostate‑cancer test. The transaction includes more than 80 patient service centers and the FDA‑approved 4Kscore test. Labcorp expects the acquired operations to generate about $250 million of revenue in the first year after closing, subject to regulatory approval.
Why it matters
The deal expands Labcorp’s specialty‑testing footprint and adds a high‑margin prostate‑cancer test, potentially boosting its revenue stream. OPKO will use the proceeds to focus on its biopharmaceutical pipeline, reducing its exposure to the diagnostic business.
Key facts
- 1Labcorp will pay $722 million in cash at closing. prnewswire.com
- 2An additional earn‑out of up to $150 million is tied to 4Kscore test revenue. prnewswire.com
- 3The total consideration can reach up to $872 million. hoodline.com
- 4The transaction includes more than 80 patient service centers. stocktitan.net
- 5Labcorp will acquire BioReference’s proprietary 4Kscore® Test. stocktitan.net
- 6Labcorp expects the acquired businesses to generate approximately $250 million in revenue in the first year after closing. prnewswire.com
Summary written by AlphAI AI Desk from 16 of 16 sources. Not investment advice. Figures are as stated by the linked sources.